Takeda Pharmaceutical Co. $TAK Shares Sold by Cornerstone Select Advisors LLC

Cornerstone Select Advisors LLC lowered its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 9.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,485 shares of the company’s stock after selling 1,130 shares during the quarter. Cornerstone Select Advisors LLC’s holdings in Takeda Pharmaceutical were worth $171,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in Takeda Pharmaceutical in the first quarter valued at approximately $37,000. Farther Finance Advisors LLC raised its holdings in Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock valued at $69,000 after acquiring an additional 1,045 shares in the last quarter. Fifth Third Bancorp raised its holdings in Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock valued at $78,000 after acquiring an additional 2,411 shares in the last quarter. GAMMA Investing LLC raised its holdings in Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after acquiring an additional 1,296 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $94,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of Takeda Pharmaceutical stock opened at $14.99 on Monday. The firm has a market capitalization of $47.70 billion, a P/E ratio of 49.97 and a beta of 0.22. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.53. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average is $14.79 and its two-hundred day moving average is $14.63.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.